In insulin-naive adults with T2D, once-weekly icodec plus semaglutide vs insulin glargine U100 showed superior glycemic control and weight loss.

The FDA has approved Enspryng (satralizumab-mwge) for thyroid eye disease in adults, offering the first at-home subcutaneous IL-6 receptor antagonist for TED.

The amylin-based analog petrelintide achieves meaningful weight reduction for adults with obesity, according to a study.

For adults taking potassium-raising medications, greater consumption of dietary potassium as part of a DASH diet is not associated with hyperkalemia.

Robert Kauffman, MD, discusses the updated ACOG clinical guidance outlining pharmacologic and nonpharmacologic interventions for menopausal symptoms.

A pooled analysis of phase 3 ICONIC data demonstrates that concomitant GLP-1 medication use does not alter skin clearance, ...

While lower-frequency IET may be sufficient to maintain BP reductions over the short term, higher frequencies are required to preserve the full CV benefits.

Researchers evaluated the incidence and risk factors for ketoacidosis among adults with type 2 diabetes receiving treatment with SGLT2 inhibitors.

GLP-1 RAs outperformed mineralocorticoid receptor antagonists (MRAs) in cardiovascular protection in resistant hypertension and obesity.

The prevalence of neurodiversity is increased among individuals diagnosed with type 2 diabetes (T2D) early in life.

Despite higher costs, Medicare Advantage does not improve glycemic control or health-related social needs in patients with type 2 diabetes.

Robotic surgery does not improve outcomes in total hip or knee replacement when compared with conventional surgery.